Acura Pharmaceuticals settles patent litigation with Sandoz
- Acura has settled a patent infringement lawsuit it had filed against Sandoz.
- Sandoz is attempting to market a generic version of Acura’s AVERSION oxycodone and has filed the ANDA.
- Under the settlement agreement, Sandoz will be able to market AVERSION oxycodone through a non-exclusive license, with a 180-day period of exclusivity
Acura filed a patent-infringement suit against Sandoz for attempting to market a generic version of Acura’s AVERSION oxycodone. The companies have settled on Sandoz being able to market AVERSION oxycodone through a non-exclusive license -- buthere is one important qualification. If Sandoz changes the structure of the drug in any way, it will have to pay royalties of 7% of the net profits.
- Pharmaceutical Business Review Acura Pharmaceuticals announces settlement of patent litigation with Sandoz